Lipitor

A new study has concluded that the class of cholesterol-lowering medications known as statins, which include Lipitor, may put users at greater risk of muscular injury.

A story in The Telegraph quotes researcher Dr. Ishak Mansi of the North Texas Health Care System in Dallas as saying: “Musculoskeletal conditions, arthropathies, injuries and pain are more common among statin users than among similar non-users. The full spectrum of statins’ musculoskeletal adverse events ...

While a recent study by Canadian researchers found a link between certain types of statins and Type 2 diabetes, the news wasn’t universally bad for users of the popular anti-cholesterol drugs.

A story in U.S. News and World Report says the researchers identified stronger statins including Lipitor as problematic.

But other types of statins performed more favorably in terms of diabetes. Study authors wrote that some forms of the drugs may even ...

A new study by Canadian researchers adds to a growing pool of evidence that Lipitor and other types of cholesterol-lowering drugs called statins put patients at a higher risk of developing diabetes.

According to a story on CTV News, researchers published the results of their study in BMJ, a journal of the British Medication Association.

The story notes that previous research has spotlighted a possible link between taking some statins and diabetes, ...

The Wall Street Journal says a dramatic sales drop in Pfizer’s anti-cholesterol medication Lipitor was behind the company’s nine percent revenue decline for the first quarter, which was worse than expected and lowered the company’s full-year outlook.

The U.S. Food and Drug Administration has recently added warnings to the label of Lipitor, advising that the drug may increase the risk of Type II diabetes. The new label also warns that Lipitor ...

Pfizer Inc. has posted lower-than-expected earnings and revenue for the first quarter, in part because of rapidly falling sales of the cholesterol drug Lipitor, Reuters reports.

Sales of the drug, formerly a cash cow for the pharmaceutical giant, plummeted 55 percent to $626 million.

The drug has been competing with cheaper generics since November. Recent health concerns about Lipitor have cropped up as well.

The U.S. Food and Drug Administration has added warnings ...